EBF3 and neoplasm: Other subtype 2 tumors (8/25, 32%) displayed mutually exclusive expression of ARR3 and EBF3 (ARR3−/EBF3+ or ARR3+/EBF3− areas), as illustrated by tumor RB617 in Fig. 4d.